ABBV vs TTD: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Trade Desk, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-09.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
The Trade Desk, Inc. · Technology
$23.08
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
TTD has more upside to fair value
(+45.0%).
TTD trades at a lower forward P/E
(25.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
TTD |
| Current Price |
$197.69 |
$23.08 |
| Fair Value Estimate |
$210.22 |
$33.47 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$10.8B |
| Forward P/E |
83.3x
|
25.3x
|
| EV / EBITDA |
23.4x
|
14.3x
|
| Price / Sales |
5.7x
|
3.6x
|
| Price / FCF |
18.7x
|
13.0x
|
| Revenue Growth YoY |
+10.0%
|
+11.8%
|
| Gross Margin |
70.2%
|
77.8%
|
| Operating Margin |
26.7%
|
20.3%
|
| Return on Equity |
-361.6%
|
16.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
7.71%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
The Trade Desk, Inc. operates a leading self-service, cloud-based programmatic advertising platform focused on demand-side platform services, primarily in connected TV and audio advertising. The company benefits from a durable competitive moat driven by network effects, high customer retention above 95%, and a founder-led management team with deep industry expertise. Despite solid revenue growth …
Accumulation Zones
| Metric |
ABBV |
TTD |
| Zone Low |
$157.66 |
$25.10 |
| Zone High |
$178.69 |
$28.45 |
| In Buy Zone? |
No
|
Yes
|